Dasatinib is an oral dual Bcr/Abl and Src family kinases inhibitor approved for treating patients with chronic myelogenous leukaemia and has been shown to have significant activity against EphA2 [40, 41]. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.